Effect of Oral NAD+ Precursors Administration on Blood NAD+ Concentration in Healthy Adults (NICO)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Pamela Sun, MBBChir MPhil (Cantab)
- Phone Number: +41 21 785 81 22
- Email: pamela.sun@rd.nestle.com
Study Contact Backup
- Name: Sylviane Oguey-Araymon
- Phone Number: +41 21 785-82 79
- Email: sylviane.oguey-araymon@rdls.nestle.com
Study Locations
-
-
Vaud
-
Lausanne, Vaud, Switzerland, 1000
- Nestle Clinical Innovation Lab
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Healthy male and female aged 18-50 years, inclusive, at enrolment
- Body mass index (BMI) between 18.5 to 27.0 kg/m².
- Able to understand and to sign a written informed consent prior to study enrolment.
- Willing and able to comply with the requirements for participation in this study.
Exclusion Criteria:
- Known history of allergy or intolerance to the investigational products.
- Any chronic medical condition and/or history of significant medical condition, which in the opinion of the site physician/ investigator may risk participant wellbeing/ safety, impede participant compliance with study procedures or ability to complete the study and/ or could confound the primary objectives of the study.
- Any acute illness or any recent medical intervention including vaccination within 14 days before the first dose of investigational product.
- Female participants who are pregnant or intending to become pregnant, lactating and/or breastfeeding. Women of childbearing potential who are not currently using medically effective forms of contraception.
- Use of prescription drugs known to potentially interact with NAD precursors within 14 days or 5 half-lives (whichever is longer) prior to the first dose of investigational product.
- Use of multivitamin/ multimineral supplements, NAD+ precursor supplementation (e.g., niacin, nicotinic acid or niacinamide), L-tryptophan supplementation and/ or any over-the- counter (OTC) medication promoting "healthy aging" or "anti-aging" or "longevity" up to 30 days before first dose of investigational product.
- On a self-restricted diet, controlled diet or special therapeutic diet up to 30 days before first dose of investigational product.
- Average alcohol consumption greater than 2 standard drinks per day over a week for males, and greater than 1 standard drink per day over a week for females. One standard drink contains 10-12 g of ethanol. Examples of standard drinks are one beer can (300 ml), one glass of wine (100 ml) or one glass of schnaps (30 ml).
- Current smoker (e.g., cigarette, tobacco, cannabis) who exceeds 5 cigarettes per week.
- Performing shift work or trans-meridian travel greater than two time zones within 14 days prior to the first dose of investigational product.
- Currently participating in another research study.
- Family or hierarchical relationships with the Clinical Innovation Lab (CIL) team.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Nicotinamide (NAM)
|
500 mg a day
|
|
Experimental: Nicotinamide Riboside (NR)
|
1000 mg a day
|
|
Experimental: Nicotinamide Mono Nucleotide (NMN)
|
1000 mg a day
|
|
Placebo Comparator: Microcrystalline cellulose
|
500 mg a day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine the extent of increase in NAD+ level in whole blood, for each NAD+ precursor (NAM, NR and NMN) compared to placebo
Time Frame: at Day 14
|
Measure the changes in whole blood NAD+ level interventions vs placebo: NAM vs placebo, NR vs placebo, NMN versus placebo by quantitative liquid chromatography-mass spectroscopy
|
at Day 14
|
|
Compare the extent of increase in NAD+ level in whole blood across the 3 NAD+ precursors (NAM, NR and NMN)
Time Frame: at Day 14
|
Measure the changes in whole blood NAD+ level across interventions: NAM vs NR, NAM vs NMN, NR vs NMN by quantitative liquid chromatography-mass spectroscopy
|
at Day 14
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Determine the extent the NAD+ precursors(NAM, NR and NMN) affect the NAD metabolome in whole blood compared to placebo
Time Frame: over 4 hours at Day 1 and at Day 14.
|
Measure the change in whole blood NAD+ metabolites iAUC (reported as microM*h) and Cmax (microM) by quantitative liquid chromatography-mass spectroscopy
|
over 4 hours at Day 1 and at Day 14.
|
|
Compare the extent the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in whole blood.
Time Frame: over 4 hours at Day 1 and at Day 14.
|
Measure the change in whole blood NAD+ metabolites iAUC (reported as microM*h) and Cmax (microM) determined by quantitative liquid chromatography-mass spectroscopy
|
over 4 hours at Day 1 and at Day 14.
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Comparer the extend the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in in plasma.
Time Frame: over 4 hours at Day 1 and at Day 14.
|
Measure the change in plasma NAD+ metabolites iAUC (reported in microM) and Cmax (microM) determined by quantitative liquid chromatography-mass spectroscopy
|
over 4 hours at Day 1 and at Day 14.
|
|
Comparer the extend the NAD+ precursors (NAM, NR and NMN) affect the NAD+ metabolome in urine
Time Frame: at baseline Day 14 versus Day 1
|
Measure the change in urine NAD+ metabolites iAUC (reported in microM) and Cmax (microM) determined by quantitative liquid chromatography-mass spectroscopy
|
at baseline Day 14 versus Day 1
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2201NR
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.